Inmed pharmaceuticals reports first quarter fiscal 2023 financial results and provides business update

Vancouver, british columbia, nov. 11, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the first quarter of fiscal year 2023, ended september 30, 2022.
INM Ratings Summary
INM Quant Ranking